Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.50.
A number of equities analysts have weighed in on ETTX shares. Wedbush reaffirmed an “outperform” rating and set a $19.00 price target on shares of Entasis Therapeutics in a research note on Tuesday, April 2nd. Zacks Investment Research lowered shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. Finally, ValuEngine lowered shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
A number of hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC raised its stake in shares of Entasis Therapeutics by 13,801.0% in the 4th quarter. FNY Investment Advisers LLC now owns 13,901 shares of the company’s stock valued at $56,000 after buying an additional 13,801 shares in the last quarter. BlackRock Inc. bought a new stake in Entasis Therapeutics in the fourth quarter valued at approximately $56,000. Janney Montgomery Scott LLC bought a new stake in Entasis Therapeutics in the fourth quarter valued at approximately $169,000. Credit Suisse AG bought a new stake in Entasis Therapeutics in the third quarter valued at approximately $757,000. Finally, Luminus Management LLC bought a new stake in Entasis Therapeutics in the third quarter valued at approximately $2,130,000. 65.40% of the stock is owned by institutional investors.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
See Also: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.